Press Releases June 26, 2026 08:30 AM

LIXTE Joins Russell Microcap Index

LIXTE Biotechnology Holdings included in the Russell Microcap Index, signaling strategic progress and enhanced investor visibility amid its AI energy infrastructure pivot.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
LIXT

LIXTE Biotechnology Holdings, Inc. has been added to the Russell Microcap Index as of June 26, 2026, reflecting its recent growth and strategic transformation from biotechnology to an AI energy infrastructure equipment and services platform. This inclusion is expected to increase visibility among institutional investors and support LIXTE's efforts in the expanding AI and hyperscale data center markets requiring advanced power and infrastructure solutions.

LIXTE Joins Russell Microcap Index
LIXT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • LIXTE joins the Russell Microcap Index, improving its market exposure and credibility among institutional investors.
  • The company is undergoing a strategic transformation into AI-focused energy infrastructure equipment and services, targeting the growing demands from AI, cloud computing, and hyperscale data centers.
  • Inclusion in the Russell Index demonstrates the company's progress and potential in the technology and energy sectors tied to AI infrastructure expansion.

BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap® Index, effective after the close of the U.S. equity markets on June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution. The reconstituted indexes will take effect at the opening of trading on Monday, June 29, 2026.

“LIXTE’s inclusion in the Russell Microcap Index represents an important milestone for the Company and reflects the significant progress we have made over the past year,” said Geordan Pursglove, Chief Executive Officer of LIXTE. “Under our new leadership team and strategic direction, we have successfully transformed the Company and enhanced shareholder value. We believe membership in the Russell Microcap Index will increase our visibility among institutional investors, broaden awareness of our growth strategy, and support our efforts to build a leading platform focused on AI energy infrastructure equipment and services. This recognition comes at a pivotal time as demand for power and infrastructure solutions continues to accelerate alongside the expansion of AI and hyperscale data centers.”

The Russell U.S. Indexes are among the most widely recognized benchmarks for institutional investors and investment managers. Membership in the Russell Microcap Index provides exposure to investment products and funds that benchmark their performance against Russell indexes.

The Russell Microcap Index measures the performance of smaller publicly traded U.S. companies and serves as a widely followed benchmark for active and passive microcap investment strategies. Russell indexes are reconstituted annually to reflect changes in the U.S. equity market and to ensure that growing companies are appropriately represented.

About LIXTE

LIXTE Biotechnology Holdings, Inc. is a holding company that historically focused on the development of innovative cancer therapies and medical technologies. The Company is currently executing a strategic transformation into an AI energy infrastructure equipment and services platform focused on supporting the rapidly growing power and infrastructure requirements of artificial intelligence, cloud computing, and hyperscale data center operators. Through this transition, LIXTE aims to capitalize on the accelerating demand for reliable, scalable, and efficient energy infrastructure solutions driven by the global expansion of AI.

For more information about LIXTE, [email protected], contact: 

General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations, [email protected]
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962


Risks

  • The successful execution of LIXTE's strategic pivot from biotechnology to AI energy infrastructure equipment and services is uncertain and may face operational challenges.
  • Market adoption and competition in the AI energy infrastructure sector could impact LIXTE's growth and financial performance.
  • General market volatility and changes in investor sentiment towards microcap stocks and technology sectors could affect LIXTE's stock performance.

More from Press Releases

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08 Jul 3, 2026 REE Automotive Announces Receipt of Nasdaq Delisting Notice Jul 3, 2026 Nayax Adds AI Layer to its MoMa Mobile App for Vending and Self-Service Operators Jul 3, 2026 CN Reports June Grain Movement Jul 3, 2026 CN to Report Second-Quarter 2026 Financial and Operating Results on July 24, 2026 Jul 3, 2026